CN115028718A - Preparation method and application of USF3 rabbit polyclonal antibody - Google Patents
Preparation method and application of USF3 rabbit polyclonal antibody Download PDFInfo
- Publication number
- CN115028718A CN115028718A CN202210505788.6A CN202210505788A CN115028718A CN 115028718 A CN115028718 A CN 115028718A CN 202210505788 A CN202210505788 A CN 202210505788A CN 115028718 A CN115028718 A CN 115028718A
- Authority
- CN
- China
- Prior art keywords
- usf3
- polyclonal antibody
- antibody
- rabbit
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
技术领域technical field
本发明涉及生物工程领域,具体涉及到一种USF3兔多克隆抗体的制备方法。The invention relates to the field of bioengineering, in particular to a preparation method of a USF3 rabbit polyclonal antibody.
背景技术Background technique
上游转录因子家族成员3(Upstream Transcription Factor Family Member 3,USF3),由2221个氨基酸组成,在不同的组织和细胞中,USF3均广泛表达。对该蛋白的结构分析表明USF3会通过形成蛋白二聚体发挥功能,它有一个bHLH结构域负责转录调控,以及还有一些丝氨酸和谷氨酰胺富集区域。已有的文献表明:USF3基因谷氨酰胺富集区域的基因缺失与甲状腺癌的易感相关,并在上皮到间质转化(EMT)中起负调控作用。因此,作为一种转录因子,USF3很有可能与肿瘤的发生发展有关系。Upstream Transcription Factor Family Member 3 (USF3), consisting of 2221 amino acids, is widely expressed in different tissues and cells. Structural analysis of the protein indicated that USF3 functions by forming protein dimers, a bHLH domain responsible for transcriptional regulation, and serine- and glutamine-rich regions. Existing literature shows that gene deletion in the glutamine-rich region of the USF3 gene is associated with susceptibility to thyroid cancer and negatively regulates epithelial-to-mesenchymal transition (EMT). Therefore, as a transcription factor, USF3 is likely to be involved in the occurrence and development of tumors.
然而,由于USF3的蛋白分子量非常大,目前市场上尚未有针对USF3蛋白设计的免疫沉淀的抗体,这对研究USF3蛋白的功能产生很大的限制,因此实现一种特异性制备可用于免疫印迹法检测USF3的蛋白显得尤为重要。However, due to the very large molecular weight of USF3 protein, there are currently no immunoprecipitated antibodies designed against USF3 protein on the market, which greatly limits the study of the function of USF3 protein. Therefore, a specific preparation can be used for western blotting. It is particularly important to detect the protein of USF3.
发明内容SUMMARY OF THE INVENTION
为了解决现有技术问题,本发明的目的在于克服已有技术存在的不足,提供一种USF3兔多克隆抗体及其制备方法,并提供一种多克隆抗体及其在细胞学和动物学检测的应用,为实现研究USF3蛋白的定量检测、最终研究USF3的功能奠定基础。In order to solve the problems of the prior art, the object of the present invention is to overcome the deficiencies of the prior art, provide a USF3 rabbit polyclonal antibody and a preparation method thereof, and provide a polyclonal antibody and its detection in cytology and zoology. The application lays the foundation for the quantitative detection of USF3 protein and the final study of the function of USF3.
为达到上述发明创造目的,本发明采用如下技术方案:In order to achieve the above-mentioned purpose of invention and creation, the present invention adopts the following technical solutions:
一种USF3兔多克隆抗体的制备方法,包括以下步骤:A preparation method of USF3 rabbit polyclonal antibody, comprising the following steps:
a)抗原制备:a) Antigen preparation:
通过原核表达,得到USF3重组蛋白片段;Through prokaryotic expression, the USF3 recombinant protein fragment was obtained;
b)免疫动物:b) Immunized animals:
将USF3重组蛋白片段作为抗原,免疫白兔;Using USF3 recombinant protein fragments as antigens, immunized white rabbits;
c)效价检测:c) titer detection:
从免疫白兔体内采集被测抗体标本,采用间接ELISA法,对抗体进行梯度稀释,并检测抗体的效价和灵敏度;The tested antibody samples were collected from the immunized white rabbits, and the indirect ELISA method was used to dilute the antibody in a gradient manner, and to detect the titer and sensitivity of the antibody;
d)多克隆抗体纯化后处理:d) Post-processing of polyclonal antibody purification:
采用抗原亲和纯化方法,得到多克隆抗体。Antigen affinity purification method was used to obtain polyclonal antibodies.
优选地,在所述步骤a)中,USF3重组蛋白序列和质粒模板,选择1-180aa,通过全基因合成构建到pET-28a-SUMO,原核表达免疫原。Preferably, in the step a), the USF3 recombinant protein sequence and plasmid template are selected from 1-180aa, constructed into pET-28a-SUMO by total gene synthesis, and the immunogen is expressed prokaryotically.
进一步优选地,在所述步骤a)中,利用软件对USF3蛋白的保守结构域和抗原表位进行分析,选择序列特异性好且包含完整结构域的区域作为抗原区,并将该区域克隆至pET-28a-SUMO载体。Further preferably, in the step a), software is used to analyze the conserved domains and antigenic epitopes of the USF3 protein, and a region with good sequence specificity and a complete domain is selected as the antigenic region, and the region is cloned into pET-28a-SUMO vector.
优选地,在所述步骤b)中,所述的USF3重组蛋白片段免疫的白兔为日本大耳白兔。Preferably, in the step b), the white rabbit immunized with the USF3 recombinant protein fragment is a Japanese white rabbit.
进一步优选地,所产生的多克隆抗体通过间接ELISA法,检测所得到的效价为1:128000。Further preferably, the titer of the produced polyclonal antibody is 1:128000 by indirect ELISA method.
优选地,在所述步骤c)中,从免疫白兔体内采集生物样本,经亲和纯化后,得到被测抗体标本;然后采用间接ELISA法,对抗体进行梯度稀释,并检测抗体的效价和灵敏度。Preferably, in the step c), a biological sample is collected from the immunized white rabbit, and after affinity purification, a sample of the antibody to be tested is obtained; then the indirect ELISA method is used to carry out gradient dilution of the antibody, and the titer of the antibody is detected and sensitivity.
优选地,在所述步骤d)中,采用Protein G亲和层析纯化方法,得到多克隆抗体。Preferably, in the step d), a protein G affinity chromatography purification method is used to obtain a polyclonal antibody.
一种多克隆抗体在检测USF3蛋白中的应用,所述多克隆抗体为本发明所述的USF3兔多克隆抗体的制备方法制备的多克隆抗体。The application of a polyclonal antibody in detecting USF3 protein, the polyclonal antibody is the polyclonal antibody prepared by the preparation method of the USF3 rabbit polyclonal antibody according to the present invention.
一种多克隆抗体在制备ELISA法检测USF3蛋白的试剂中的应用,所述多克隆抗体为本发明所述的USF3兔多克隆抗体的制备方法制备的多克隆抗体。The application of a polyclonal antibody in the preparation of a reagent for detecting USF3 protein by ELISA method, the polyclonal antibody is the polyclonal antibody prepared by the preparation method of the USF3 rabbit polyclonal antibody according to the present invention.
本发明与现有技术相比较,具有如下显而易见的突出实质性特点和显著优点:Compared with the prior art, the present invention has the following obvious outstanding substantive features and significant advantages:
1.本发明方法对USF3蛋白全长的抗原性进行分析,选择高疏水性的片段,利用工程菌株表达、纯化得到的高纯度USF3蛋白作为抗原,通过免疫日本大耳白兔获得抗血清纯化后得到的抗体间接ELISA效价达到1:128000,所述多克隆抗体可以特异识别原核表达的重组USF3蛋白,并能检测C57BL/6J小鼠组织和不同细胞中的内源USF3蛋白,USF3蛋白的兔多克隆抗体的构建为动物水平和细胞水平中该蛋白的检测提供了物质和技术支撑;1. The method of the present invention analyzes the antigenicity of the full-length USF3 protein, selects highly hydrophobic fragments, uses the high-purity USF3 protein expressed and purified by the engineered strain as the antigen, and obtains antiserum by immunizing Japanese white rabbits. The obtained antibody has an indirect ELISA titer of 1:128000. The polyclonal antibody can specifically recognize the recombinant USF3 protein expressed in prokaryotic cells, and can detect endogenous USF3 protein in C57BL/6J mouse tissues and different cells, and rabbits with USF3 protein. The construction of polyclonal antibodies provides material and technical support for the detection of the protein in animal and cellular levels;
2.本发明多克隆抗体为实现研究转录因子USF3在不同组织器官及细胞的定性、定量检测奠定基础。2. The polyclonal antibody of the present invention lays a foundation for realizing the qualitative and quantitative detection of the transcription factor USF3 in different tissues, organs and cells.
附图说明Description of drawings
图1为本发明优选实施例的Mus musculus USF3保守结构域分析结果图。Fig. 1 is a diagram showing the analysis result of the conserved structural domain of Mus musculus USF3 according to a preferred embodiment of the present invention.
图2为本发明优选实施例的Mus musculus USF3抗原表位分析图。Fig. 2 is the analysis diagram of the Mus musculus USF3 antigenic epitope according to the preferred embodiment of the present invention.
图3为本发明优选实施例的USF3重组蛋白片段SDS-PAGE电泳结果图。Figure 3 is a graph showing the results of SDS-PAGE electrophoresis of USF3 recombinant protein fragments according to a preferred embodiment of the present invention.
图4为本发明优选实施例的多克隆抗体纯化后的SDS-PAGE电泳结果图。FIG. 4 is a graph showing the result of SDS-PAGE electrophoresis after purification of the polyclonal antibody according to the preferred embodiment of the present invention.
图5为本发明优选实施例的多克隆抗体滴度结果图。FIG. 5 is a graph showing the results of polyclonal antibody titer according to the preferred embodiment of the present invention.
图6为本发明优选实施例的多克隆抗体特异性检测C57BL/6J小鼠组织器官和不同细胞株中USF3表达的Western blot结果图。Figure 6 is a diagram showing the Western blot results of the specific detection of USF3 expression in C57BL/6J mouse tissues, organs and different cell lines by the polyclonal antibody according to the preferred embodiment of the present invention.
具体实施方式Detailed ways
下面结合附图,对本发明的具体实施方式进行详细描述,但应当理解本发明的保护范围并不受具体实施方式的限制。The specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings, but it should be understood that the protection scope of the present invention is not limited by the specific embodiments.
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。The experimental methods used in the following examples are conventional methods unless otherwise specified.
下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径可购得。Materials, reagents, etc. used in the following examples can be purchased from commercial sources unless otherwise specified.
USF3是转录因子,对其结构域分析如图1,其抗原表位分析如图2,选择1-180aa段,此段序列特异性较好,包含完整结构域,且抗原表位预测性质较好,有一定的二级结构,利于蛋白表达。USF3 is a transcription factor. Its structural domain analysis is shown in Figure 1, and its antigenic epitope analysis is shown in Figure 2. The 1-180aa segment is selected. This segment has better sequence specificity, contains a complete structural domain, and has good antigenic epitope prediction properties. , has a certain secondary structure, which is conducive to protein expression.
以下结合具体的实施例子对上述方案做进一步说明,本发明的优选实施例详述如下:The above scheme will be further described below in conjunction with specific embodiments, and preferred embodiments of the present invention are described in detail as follows:
在本实施例中,一种USF3兔多克隆抗体的制备方法,包括以下步骤:In the present embodiment, a preparation method of USF3 rabbit polyclonal antibody, comprising the following steps:
1.免疫抗原的制备:1. Preparation of immunizing antigens:
(1)重组蛋白USF3片段表达菌株构建、菌体培养及裂解(1) Construction of recombinant protein USF3 fragment expression strain, bacterial culture and lysis
USF3重组蛋白片段氨基酸序列:USF3 recombinant protein fragment amino acid sequence:
MPEMTEHETPTKKQHRKKNRETHNAVERHRKKKINAGINRIGELIPCSPALKQSKNMILDQAFKYITELKRQNDELLLNGGSSEQAEEIKKLRKQLEEIQKENGRYIELLKANDICLYDDPTIHWKGNLKTSKVSVVIPSDQVQKNIIVYSNGSQPGGNSQGTAVQGITFNVGHGLQKQTMPEMTEHETPTKKQHRKKNRETHNAVERHRKKKINAGINRIGELIPCSPALKQSKNMILDQAFKYITELKRQNDELLLNGGSSEQAEEIKKLRKQLEEIQKENGRYIELLKANDICLYDDPTIHWKGNLKTSKVSVVIPSDQVQKNIIVYSNGSQPGGNSQGTAVQGITFNVGHGLQKQT
用高保真Fastpfu进行PCR扩增,扩增到的PCR产物经(2.0%)琼脂糖凝胶电泳鉴定后,将目的条带切胶回收,用Universal DNA纯化回收试剂盒(天根)回收,回收产物经酶切、胶回收与进行同样酶切、胶回收处理的pET28a质粒片段于4℃过夜连接,转化Trans10感受态细胞,挑取克隆,进行菌落PCR鉴定,阳性克隆进行测序。High-fidelity Fastpfu was used for PCR amplification. After the amplified PCR product was identified by (2.0%) agarose gel electrophoresis, the target band was cut into gel and recovered, and recovered with Universal DNA purification and recovery kit (Tiangen). The product was digested and gel-recovered and the pET28a plasmid fragment subjected to the same enzyme-digestion and gel recovery treatment was ligated at 4°C overnight, transformed into Trans10 competent cells, clones were picked, colony PCR identification was performed, and positive clones were sequenced.
将鉴定正确的重组表达载体pET28a-USF3转化到E.coli Rosetta感受态细胞,菌液涂布于含卡那霉素(50μg/mL)的LB平板上,37℃过夜培养。次日在平板上挑取单克隆接种含相同浓度卡那霉素的液体LB培养基中37℃过夜培养。第二天以1%接种量接种,于37℃培养至OD600为0.6,加入0.8mM IPTG37℃处理4小时诱导表达蛋白。诱导结束将菌液用尿素溶解,收集上清。The correctly identified recombinant expression vector pET28a-USF3 was transformed into E. coli Rosetta competent cells, and the bacterial solution was spread on LB plates containing kanamycin (50 μg/mL) and cultured at 37°C overnight. The next day, pick a single clone on the plate and inoculate it in liquid LB medium containing the same concentration of kanamycin for overnight culture at 37°C. The next day, it was inoculated with 1% of the inoculum, cultured at 37°C to an OD 600 of 0.6, and added 0.8mM IPTG at 37°C for 4 hours to induce protein expression. After induction, the bacterial solution was dissolved with urea, and the supernatant was collected.
(2)重组蛋白纯化(2) Purification of recombinant protein
菌体裂解液上清纯化,收集蛋白峰组分并经SDS-PAGE检测蛋白样品的纯度。图3为USF3重组蛋白片段SDS-PAGE电泳结果图。图3中各泳道分别为10ng,5ng,1ng,500pg抗原;抗体稀释比例为1:1000。通过图3可得,经过凝胶过滤最后获得电泳纯的USF3蛋白,分子量约为35KDa。The supernatant of the bacterial lysate was purified, and the protein peak fractions were collected and the purity of the protein samples was detected by SDS-PAGE. Figure 3 is a graph showing the results of SDS-PAGE electrophoresis of USF3 recombinant protein fragments. Each lane in Figure 3 is 10ng, 5ng, 1ng, and 500pg antigen respectively; the antibody dilution ratio is 1:1000. As can be seen from Figure 3, electrophoresis-pure USF3 protein was finally obtained through gel filtration, with a molecular weight of about 35KDa.
2.免疫动物:2. Immunized animals:
用上述质控合格的USF3重组蛋白片段作为抗原免疫2只4月龄的SPF级日本大耳白兔,抗原与等体积完全弗氏佐剂(第一次免疫)和不完全弗氏佐剂(加强免疫)混合并进行乳化,充分混合至油包水状态进行皮下免疫,3次加强免疫,每次免疫间隔周期2-3周,之后采血进行效价检测,具体免疫次数及免疫剂量如表1所示:Two 4-month-old SPF Japanese white rabbits were immunized with the above quality-controlled USF3 recombinant protein fragments as antigens, with equal volumes of complete Freund's adjuvant (the first immunization) and incomplete Freund's adjuvant ( Booster immunization) mixed and emulsified, fully mixed to the water-in-oil state for subcutaneous immunization, 3 booster immunizations, each immunization interval of 2-3 weeks, then blood was collected for titer detection, the specific immunization times and immunization dose are shown in Table 1 shown:
表1.免疫次数及免疫剂量表Table 1. Immunization frequency and immunization dose table
3.多克隆抗体纯化:3. Polyclonal antibody purification:
收集后的抗血清用pET-28a-SUMO-USF3蛋白作抗原亲和纯化,得到浓缩后的抗体经过SDS-PAGE检测纯度。图4为多克隆抗体纯化后的SDS-PAGE电泳结果图。采用的稀释比例和测得的E7879抗体效价表如表2所示:The collected antiserum was purified by antigen affinity with pET-28a-SUMO-USF3 protein, and the concentrated antibody was tested for purity by SDS-PAGE. Figure 4 is a graph showing the results of SDS-PAGE electrophoresis after purification of the polyclonal antibody. The dilution ratio used and the measured E7879 antibody titer table are shown in Table 2:
表2.对抗体进行梯度稀释,并检测抗体的效价结果表Table 2. The results of serial dilution of antibodies and detection of antibody titers
检测结果如表2和图4所示,将抗体-20℃保存,避免冻结。The test results are shown in Table 2 and Figure 4. Store the antibody at -20°C to avoid freezing.
4.多克隆抗体的效价测定:4. Determination of the titer of polyclonal antibodies:
将纯化好的多克隆抗体,以重组蛋白USF3为抗原,用间接ELISA方法检测其效价。图5为多克隆抗体滴度结果图。其中图5第一个插图对应的多克隆抗体滴度测定:The titer of the purified polyclonal antibody was detected by indirect ELISA with recombinant protein USF3 as antigen. Figure 5 is a graph showing the results of polyclonal antibody titers. The polyclonal antibody titer determination corresponding to the first inset of Figure 5:
Lane 1:C57小鼠脾脏组织蛋白提取液30ug,用E7879 10ug/ml孵育;Lane 1: C57 mouse spleen tissue protein extract 30ug, incubated with E7879 10ug/ml;
Lane 2:C57小鼠肝脏组织蛋白提取液30ug,用E7879 10ug/ml孵育;Lane 2: C57 mouse liver tissue protein extract 30ug, incubated with E7879 10ug/ml;
Lane 3:C57小鼠脑组织蛋白提取液30ug,用E7879 10ug/ml孵育;Lane 3: C57 mouse brain tissue protein extract 30ug, incubated with E7879 10ug/ml;
Lane 4:C57小鼠肠组织蛋白提取液30ug,用E7879 10ug/ml孵育;Lane 4: C57 mouse intestinal tissue protein extract 30ug, incubated with E7879 10ug/ml;
Lane 5:C57小鼠肾脏组织蛋白提取液30ug,用E7879 10ug/ml孵育。Lane 5: C57 mouse kidney tissue protein extract 30ug, incubated with E7879 10ug/ml.
其中图5第二个插图对应的多克隆抗体滴度测定:The polyclonal antibody titer determination corresponding to the second inset of Figure 5:
Lane 1:SW480肠癌细胞蛋白提取液30ug,用E7879 10ug/ml孵育;Lane 1: SW480 intestinal cancer cell protein extract 30ug, incubated with E7879 10ug/ml;
Lane 2:U251脑胶质瘤细胞蛋白提取液30ug,用E7879 10ug/ml孵育;Lane 2: U251 glioma cell protein extract 30ug, incubated with E7879 10ug/ml;
Lane 3:293T细胞蛋白提取液30ug,用E7879 10ug/ml孵育。Lane 3: 293T cell protein extract 30ug, incubated with E7879 10ug/ml.
通过图5可知,经ELISA测定,纯化得到的多克隆抗体抗滴度为1:128000。As can be seen from Figure 5, the anti-titer of the purified polyclonal antibody was 1:128000 as determined by ELISA.
5.多克隆抗体特异性检测:5. Polyclonal antibody specific detection:
分别提取C57BL/6J小鼠脾、肝、脑、肠、肾和肠癌细胞SW480、脑胶质瘤U251细胞以及293T细胞的蛋白,跑SDS-PAGE胶,转膜用纯化多克隆抗体作为一抗,HRP Goat Anti-Rabbit IgG(H+L)为二抗,用Odyssey CLx红外激光双色图像分析系统分析western检测结果,通过图6可知,纯化得到的多克隆抗体能特异识别内源样本中USF3。The proteins of C57BL/6J mouse spleen, liver, brain, intestine, kidney and intestinal cancer cells SW480, glioma U251 cells and 293T cells were extracted, run on SDS-PAGE gel, and transferred to membrane with purified polyclonal antibody as primary antibody , HRP Goat Anti-Rabbit IgG (H+L) was used as the secondary antibody, and the western detection results were analyzed by the Odyssey CLx infrared laser two-color image analysis system. As shown in Figure 6, the purified polyclonal antibody can specifically recognize USF3 in endogenous samples.
前述对本发明的具体示例性实施方案的描述是为了说明和例证的目的。这些描述并非想将本发明限定为所公开的精确形式,并且很显然,根据上述教导,可以进行很多改变和变化。对示例性实施例进行选择和描述的目的在于解释本发明的特定原理及其实际应用,从而使得本领域的技术人员能够实现并利用本发明的各种不同的示例性实施方案以及各种不同的选择和改变。本发明的范围意在由权利要求书及其等同形式所限定。The foregoing descriptions of specific exemplary embodiments of the present invention have been presented for purposes of illustration and description. These descriptions are not intended to limit the invention to the precise form disclosed, and obviously many changes and modifications are possible in light of the above teachings. The exemplary embodiments were chosen and described for the purpose of explaining certain principles of the invention and their practical applications, to thereby enable others skilled in the art to make and utilize various exemplary embodiments and various different aspects of the invention. Choose and change. The scope of the invention is intended to be defined by the claims and their equivalents.
本发明上述实施例涉及一种生物工程技术领域的一种USF3兔多克隆抗体的制备方法,所述多克隆抗体的制备方法,USF3蛋白序列和质粒模板,选择1-180aa,通过全基因合成构建到pET-28a-SUMO,原核表达免疫原;然后将USF3重组蛋白片段作为抗原免疫两只实验级日本大耳白兔,然后采集亲和纯化后的抗体;再进行效价检测;最后进行多克隆抗体亲和纯化及western验证。本发明上述实施例制备的多克隆抗体为实现研究转录因子USF3在不同组织器官及细胞的定性、定量检测奠定基础。The above embodiments of the present invention relate to a method for preparing a USF3 rabbit polyclonal antibody in the field of bioengineering technology. The method for preparing the polyclonal antibody, USF3 protein sequence and plasmid template, select 1-180aa, and construct by whole gene synthesis To pET-28a-SUMO, prokaryotic expression of the immunogen; then the USF3 recombinant protein fragment was used as an antigen to immunize two experimental Japanese white rabbits, and then the affinity-purified antibodies were collected; then the titer was tested; finally, polyclonal Antibody affinity purification and western verification. The polyclonal antibodies prepared in the above embodiments of the present invention lay a foundation for realizing the qualitative and quantitative detection of the transcription factor USF3 in different tissues, organs and cells.
上面对本发明实施例结合附图进行了说明,但本发明不限于上述实施例,还可以根据本发明的发明创造的目的做出多种变化,凡依据本发明技术方案的精神实质和原理下做的改变、修饰、替代、组合或简化,均应为等效的置换方式,只要符合本发明的发明目的,只要不背离本发明的技术原理和发明构思,都属于本发明的保护范围。The embodiments of the present invention have been described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned embodiments, and various changes can also be made according to the purpose of the invention and creation of the present invention. Changes, modifications, substitutions, combinations or simplifications should be equivalent substitution methods, as long as they meet the purpose of the present invention, as long as they do not deviate from the technical principles and inventive concepts of the present invention, all belong to the protection scope of the present invention.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210505788.6A CN115028718A (en) | 2022-05-10 | 2022-05-10 | Preparation method and application of USF3 rabbit polyclonal antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210505788.6A CN115028718A (en) | 2022-05-10 | 2022-05-10 | Preparation method and application of USF3 rabbit polyclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115028718A true CN115028718A (en) | 2022-09-09 |
Family
ID=83121957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210505788.6A Pending CN115028718A (en) | 2022-05-10 | 2022-05-10 | Preparation method and application of USF3 rabbit polyclonal antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115028718A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100113297A1 (en) * | 2007-02-26 | 2010-05-06 | Centre Rene Huguenin | Method for predicting the occurrence of metastasis in breast cancer patients |
| CN108892724A (en) * | 2018-07-09 | 2018-11-27 | 中国农业科学院生物技术研究所 | A kind of preparation method of Vip3Aa20 rabbit polyclonal antibody |
-
2022
- 2022-05-10 CN CN202210505788.6A patent/CN115028718A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100113297A1 (en) * | 2007-02-26 | 2010-05-06 | Centre Rene Huguenin | Method for predicting the occurrence of metastasis in breast cancer patients |
| CN108892724A (en) * | 2018-07-09 | 2018-11-27 | 中国农业科学院生物技术研究所 | A kind of preparation method of Vip3Aa20 rabbit polyclonal antibody |
Non-Patent Citations (2)
| Title |
|---|
| ATLAS ANTIBODIES: "HPA029245", 《PRODUCT SPECIFICATION》, 12 January 2020 (2020-01-12), pages 1 * |
| YA WANG等: "Osteoporosis genome-wide association study variant c.3781 C>A is regulated by a novel anti-osteogenic factor miR-345-5p", 《HUM MUTAT》, vol. 41, no. 3, 12 January 2020 (2020-01-12), pages 709 - 718 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN119912558B (en) | Monoclonal antibody for bovine nodular skin disease virus L1R protein | |
| CN108659125B (en) | Monoclonal antibody of anti-helicobacter pylori protein, cell strain, preparation method and application thereof | |
| CN116178537A (en) | Anti-Calretinin protein monoclonal antibody and its cell line, preparation method and application | |
| CN118064473A (en) | Preparation and application of monoclonal antibody against major capsid protein of largemouth bass iridovirus LMBV | |
| CN105695417B (en) | One plant of hybridoma cell strain for secreting Mycoplasma bovis monoclonal antibody and its application | |
| CN106399294B (en) | A kind of preparation of the monoclonal antibody 7H8 of anti-human Procalcitonin protein N terminal epitope | |
| CN104829704A (en) | Phosphatidylinositol proteoglycan GPC3 protein fragment, application thereof and hybridoma cell strain prepared therewith | |
| CN113845592B (en) | Anti-CK5/6 protein monoclonal antibody and its cell line, preparation method and application | |
| CN113583120B (en) | Monoclonal antibody against CK20 protein, cell strain, preparation method and application thereof | |
| CN115028718A (en) | Preparation method and application of USF3 rabbit polyclonal antibody | |
| CN103214573B (en) | Anti human LOC339524 protein monoclonal antibody and a hybridomas cell strain and the purpose thereof | |
| CN116120437B (en) | anti-HBsAg protein monoclonal antibody and cell strain, preparation method and application thereof | |
| CN117362424A (en) | Helicobacter pylori resistant monoclonal antibody and application thereof | |
| CN116813772A (en) | anti-TREM 2 monoclonal antibody and application thereof | |
| CN115786274A (en) | A kind of tilapia Igλ monoclonal antibody and its application | |
| CN116903750A (en) | anti-PIP 4K2A splice variant polyclonal antibody and application thereof in liver cancer diagnosis | |
| CN117229394B (en) | A monoclonal antibody against Toxoplasma gondii autophagy-associated protein 8, its preparation method, and its application. | |
| CN101671394B (en) | Antibody of anti hAPE1 protein and preparation method thereof as well as kit applying antibody | |
| CN107383200B (en) | Preparation method and application of mouse-derived anti-human IgE monoclonal antibody | |
| CN107254448B (en) | Duck antigen transfer related protein TAP2 monoclonal antibody, and preparation method and application thereof | |
| CN105273082A (en) | Method for producing GFP polyclonal antibody | |
| CN119841945B (en) | Anti-human TRPS1 monoclonal antibody, and preparation method and application thereof | |
| CN119176873B (en) | Anti-smooth muscle myosin monoclonal antibody, preparation method and application thereof | |
| CN119119261B (en) | An anti-CK5&6 antibody and its application | |
| CN113307875B (en) | Monoclonal antibody for resisting TCR beta F1 protein, cell strain, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |
